Genitourinary Cancers | Specialty

Sequencing Approaches in Metastatic Renal Cell Carcinoma

July 11th 2018

Disease Progression in Patients with Metastatic RCC

July 11th 2018

Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC

July 11th 2018

VEGF TKI + Immunotherapy Combinations for mRCC

July 11th 2018

Deferred Therapy for Favorable-Risk mRCC Patients

July 11th 2018

Selecting Immunotherapy versus VEGF TKI for mRCC

July 11th 2018

Risk Stratification for Metastatic Renal Cell Carcinoma

July 11th 2018

mRCC: Cytoreductive Nephrectomy in the Modern Era

July 11th 2018

mRCC Patient Selection for Ipilimumab/Nivolumab

July 11th 2018

Newly Diagnosed Metastatic Renal Cell Carcinoma

July 11th 2018

Dr. Gupta on Impact of Pembrolizumab Plus Bevacizumab Findings in RCC

July 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the impact of the phase Ib/II results of pembrolizumab (Keytruda) plus bevacizumab (Avastin) in patients with metastatic renal cell carcinoma.

Localized Bladder Cancer Paradigm Still Faces Obstacles

July 9th 2018

Brock O’Neil, MD, discusses the struggles with treating localized bladder cancer in both the neoadjuvant and adjuvant settings, as well as the advancements with robotic cystectomy.

Dr. Grivas on Ongoing Trials in Advanced Bladder Cancer

July 7th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses ongoing trials in advanced bladder cancer.

Expert Elaborates on Emerging Advances in Bladder Cancer Care

July 6th 2018

Petros Grivas, MD, PhD, discusses ongoing clinical trials exploring novel approaches with the potential to change practice in advanced bladder cancer.

Expert Highlights Atezolizumab/Bevacizumab Combo in RCC

July 6th 2018

Brian I. Rini, MD, discusses atezolizumab plus bevacizumab as an effective frontline combination in renal cell carcinoma, as well as patient reported outcomes with the regimen.

Expert Shares Upfront Sequencing Strategies in mRCC

July 6th 2018

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Dr. Choueiri Discusses Checkpoint Inhibitors in RCC

July 4th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).

Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC

July 3rd 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

MRI Combination Techniques Hone Accuracy of Prostate Cancer Diagnosis

July 2nd 2018

Several studies presented at this year’s American Urological Association meeting underscored the value of multiparametric magnetic resonance imaging in the diagnosis and management of prostate cancer.

Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

June 29th 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses combination immunotherapy in the treatment of patients with bladder cancer.